NCT01663233 - Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine | Biotech Hunter

Enrollment

266

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Essential Hypertension

Interventions

DRUG

LCZ696

LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.

DRUG

Amlodipine

Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.

DRUG

Placebo

Matching placebo to LCZ696

Trial Locations (28)

112

Novartis Investigative Site, Taipei

114

Novartis Investigative Site, Taipei

1000

Novartis Investigative Site, Manila

1100

Novartis Investigative Site, Quezon City

1102

Novartis Investigative Site, Quezon City

1441

Novartis Investigative Site, Valenzuela

10002

Novartis Investigative Site, Taipei

40447

Novartis Investigative Site, Taichung

56000

Novartis Investigative Site, Kuala Lumpur

94300

Novartis Investigative Site, Kuching

200025

Novartis Investigative Site, Shanghai

300142

Novartis Investigative Site, Tianjin

400042

Novartis Investigative Site, Chongqing

050000

Novartis Investigative Site, Shijiazhuang

133-0061

Novartis Investigative Site, Edogawa-ku

124-0024

Novartis Investigative Site, Katsushika-ku

204-0021

Novartis Investigative Site, Kiyose

186-0001

Novartis Investigative Site, Kunitachi

150-0002

Novartis Investigative Site, Shibuya-ku

142-0063

Novartis Investigative Site, Shinagawa-ku

171-0021

Novartis Investigative Site, Toshima-ku

602-739

Novartis Investigative Site, Busan

220-701

Novartis Investigative Site, Wŏnju

410-719

Novartis Investigative Site, Koyang

150-713

Novartis Investigative Site, Seoul

705-703

Novartis Investigative Site, Daegu

705-718

Novartis Investigative Site, Daegu